Morgan Stanley Inhibikase Therapeutics, Inc. Transaction History

Morgan Stanley

  • $1.23 Trillion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
BUY
$0.63 - $1.44 $6,300 - $14,400
10,000 New
10,000 $7,000
Q1 2022

May 13, 2022
SELL
$1.03 - $1.77 $2 - $3
-2 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$1.38 - $2.17 $2 - $4
2 New
2 $0

Others Institutions Holding IKT

# of Institutions
2
Shares Held
1.03M
Call Options Held
0
Put Options Held
0
View Full List

About Inhibikase Therapeutics, Inc.

IKT Quotes by TradingView
  • Ticker IKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,227,100
  • Market Cap $33.8M
  • Description
  • Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...
More about IKT
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email